Synthetic Cationic Peptide IDR-1018 Modulates Human Macrophage Differentiation

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Pena, Olga M ^a   Afacan, Nicole ^a   Pistolic, Jelena ^a   Chen, Carol ^a   Madera, Laurence ^a   Falsafi, Reza ^a   Fjell, Christopher D ^a   Hancock, Robert E W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CYCLOOXYGENASE 2; IDR 1018; IMMUNOMODULATING AGENT; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12P35; INTERLEUKIN 12P40; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STAT3 PROTEIN; SYNTHETIC PEPTIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; INFLAMMATION; MACROPHAGE; MACROPHAGE FUNCTION; MULTIDRUG RESISTANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMS BIOLOGY; WOUND HEALING;

ANTIMICROBIAL CATIONIC PEPTIDES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; MACROPHAGES; PHAGOCYTOSIS; TRANSCRIPTION FACTORS;

EID: 84872028125     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052449     Document Type: Article

References (47)

1. Afacan NJ, Yeung AT, Pena OM, Hancock REW, (2012) Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr Pharm Des 18: 807-819.
2. Hancock REW, Nijnik A, Philpott DJ, (2012) Modulating immunity as a therapy for bacterial infections. Nat Rev Micro 10: 243-254.
3. Fjell CD, Hiss JA, Hancock REW, Schneider G, (2012) Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11: 37-51.
4. Wieczorek M, Jenssen H, Kindrachuk J, Scott WRP, Elliott M, et al. (2010) Structural studies of a peptide with immune modulating and direct antimicrobial activity. Chem Biol 17: 970-980.
5. Achtman AH, Pilat S, Law CW, Lynn DJ, Janot L, et al. (2012) Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. SciTrans Med 4: 135ra164.
6. Sica A, Mantovani A, (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 122: 787-795.
7. Cassetta L, Cassol E, Poli G, (2011) Macrophage polarization in health and disease. Immunol Res 53: 11-24.
8. Mosser DM, Edwards JP, (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8: 958-969.
9. Martinez FO, Helming L, Gordon S, (2009) Alternative activation of macrophages: an immunologic functional perspective. Ann Rev Immunol 27: 451-483.
10. Pena OM, Pistolic J, Raj D, Fjell CD, Hancock REW, (2011) Endotoxin tolerance represents a distinctive state of alternative polarization (M2) in human mononuclear cells. J Immunol 186: 7243-7254.
11. Martinez FO, Gordon S, Locati M, Mantovani A, (2006) Transcriptional profiling of the human monocyte to macrophage differentiation and polarization: new molecules and patterns of gene expression. Journal Immunol 177: 7303-7311.
12. Gordon S, Taylor PR, (2005) Monocyte and macrophage heterogeneity. Nat Rev Immunol 5: 953-964.
13. Martinez FO, Sica A, Mantovani A, Locati M, (2008) Macrophage activation and polarization. Front Biosci 13: 453-461.
14. Escribese MM, Sierra-Filardi E, Nieto C, Samaniego R, Sanchez-Torres C, et al. (2012) The Prolyl Hydroxylase PHD3 identifies proinflammatory macrophages and Its expression is regulated by Activin A. J Immunol (in press).
15. Sierra-Filardi E, Vega MA, Sanchez-Mateos P, Corbi AL, Puig-Kreger A, (2010) Heme Oxygenase-1 expression in M-CSF-polarized M2 macrophages contributes to LPS-induced IL-10 release. Immunobiol 215: 788-795.
16. Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, et al. (2010) The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 11: 936-944.
17. Sierra-Filardi E, Puig-Kreger A, Blanco FJ, Nieto C, Bragado R, et al. (2011) Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 117: 5092-5101.
18. Del Fresno C, Garcia-Rio F, Gomez-Pina V, Soares-Schanoski A, Fernandez-Ruiz I, et al. (2009) Potent phagocytic activity with impaired antigen presentation identifying lipopolysaccharide-tolerant human monocytes: demonstration in isolated monocytes from cystic fibrosis patients. J Immunol 182: 6494-6507.
19. Biswas SK, Lopez-Collazo E, (2009) Endotoxin tolerance: new mechanisms, molecules and clinical significance. Trends Immunol 30: 475-487.
20. Lawrence T, Natoli G, (2011) Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol 11: 750-761.
21. Ganster RW, Taylor BS, Shao L, Geller DA, (2001) Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kB. Proc Nat Acad Sci 98: 8638-8643.
22. Sica A, Rubino L, Mancino A, Larghi P, Porta C, et al. (2007) Targeting tumour-associated macrophages. Expert Opin Ther Targets 11: 1219-1229.
23. Kwon H, Thierry-Mieg D, Thierry-Mieg J, Kim H-P, Oh J, et al. (2009) Analysis of interleukin-21-induced PRDM1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 31: 941-952.
24. Mookherjee N, Brown KL, Bowdish DME, Doria S, Falsafi R, et al. (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176: 2455-2464.
25. Nijnik A, Pistolic J, Wyatt A, Tam S, Hancock REW, (2009) Human cathelicidin peptide LL-37 modulates the effects of IFN-γ on APCs. J Immunol 183: 5788-5798.
26. Darveau RP, Hancock RE, (1983) Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol 155: 831-838.
27. Pfaffl M, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
28. Lynn DJ, Winsor GL, Chan C, Richard N, Laird MR, et al. (2008) InnateDB: facilitating systems-level analyses of the mammalian innate immune response. Mol Syst Biol 4.
29. Jersmann HPA, Ross KA, Vivers S, Brown SB, Haslett C, et al. (2003) Phagocytosis of apoptotic cells by human macrophages: analysis by multiparameter flow cytometry. Cytometry A 51A: 7-15.
30. Gordon S, (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23-35.
31. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, et al. (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25: 677-686.
32. Varin A, Gordon S, (2009) Alternative activation of macrophages: Immune function and cellular biology. Immunobiol 214: 630-641.
33. Steinstraesser L HT, Schulte M, Kueckelhaus M, Jacobsen F, Mersch EA, Stricker I, Afacan N, Jenssen H, Hancock REW, Kindrachuk J, (2012) Innate defence regulator peptide 1018 in wound healing and wound infection. PLoS ONE (in press).
34. Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, et al. (2009) M2 Macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than M1 cells in vitro. J Immunol 182: 4415-4422.
35. Del Fresno C, Gomez-Pina V, Lores V, Soares-Schanoski A, Fernandez-Ruiz I, et al. (2008) Monocytes from cystic fibrosis patients are locked in an LPS tolerance state: down-regulation of TREM-1 as putative underlying mechanism. PLoS ONE 3: e2667.
36. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, et al. (2007) PPARγ activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metabol 6: 137-143.
37. El Chartouni C, Schwarzfischer L, Rehli M, (2010) Interleukin-4 induced interferon regulatory factor (Irf) 4 participates in the regulation of alternative macrophage priming. Immunobiol 215: 821-825.
38. Lang R, (2005) Tuning of macrophage responses by Stat3-inducing cytokines: molecular mechanisms and consequences in infection. Immunobiol 210: 63-76.
39. Stein M, Keshav S, Harris N, Gordon S, (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 176: 287-292.
40. Lolmede K, Campana L, Vezzoli M, Bosurgi L, Tonlorenzi R, et al. (2009) Inflammatory and alternatively activated human macrophages attract vessel-associated stem cells, relying on separate HMGB1- and MMP-9-dependent pathways. J Leukoc Biol 85: 779-787.
41. Scott M, Dullaghan E, Mookherjee N, Glavas N, Waldbrook M, et al. (2007) An anti-infective peptide that selectively modulates the innate immune response. Nat Biotechnol 25: 465-472.
42. Nijnik A, Madera L, Ma S, Waldbrook M, Elliott MR, et al. (2010) Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J Immunol 184: 2539-2550.
43. Benoit M, Desnues Bt, Mege J-L, (2008) Macrophage polarization in bacterial infections. Journal of Immunol 181: 3733-3739.
44. Koh TJ, DiPietro LA, (2011) Inflammation and wound healing: the role of the macrophage. Exp Rev Mol Med 13: null-null.
45. Ramos R, Silva JP, Rodrigues AC, Costa R, Guardao L, et al. (2011) Wound healing activity of the human antimicrobial peptide LL37. Peptides 32: 1469-1476.
46. Semple F, Dorin JR, (2012) β-Defensins: multifunctional modulators of infection, inflammation and more? J Inn Immun 4: 337-348.
47. Murray PJ, Wynn TA, (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11: 723-737.